Product Description
Adrenomedullin is a 52 aa peptide with several functions, including vasodilation, regulation of hormone secretion, promotion of angiogenesis, and antimicrobial activity. (Sourced from: https://www.ncbi.nlm.nih.gov/gene/133)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Crohn Disease|CADASIL|Dementia, Multi-Infarct|Colitis, Ulcerative
Phase 1: Crohn Disease|Colitis, Ulcerative|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AML2220 | N/A |
Unknown status |
Acute Myeloid Leukemia |
2024-06-01 |
|
| AMCAD | P2 |
Completed |
CADASIL|Dementia, Multi-Infarct |
2023-01-23 |
|
| Adults | P1 |
Completed |
Crohn Disease|Colitis, Ulcerative |
2022-12-19 |
|
| JapicCTI-183947 | P2 |
Unknown |
Crohn Disease |
2020-03-31 |